We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.
The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.
We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on helping healthcare clients find better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes.
Mobiquity is a full-service digital consultancy that delivers compelling digital products and services that serve a purpose by blending strategy, creative and engineering. The company solves business challenges with a dedicated sector agnostic team, to deliver ‘beyond the medicine’ digital innovation to support patients and healthcare professionals.
ADHERENCE BY DESIGN
Cross sector design principles that will anchor your DTx in the hearts and minds of your users
Design is crucial to drive adoption and adherence of any digital product, especially when your sector is increasingly transitioning from physical to digital interactions. How you use design to connect with patients on a rational and emotional level will determine your products success. Many other sectors have been on this journey. What can DTx learn from them and how can these design principles be applied?
Cognoa’s digital diagnostics and personalized therapeutics improve the timeliness, scale, and effectiveness of behavioral healthcare. Their first clinically-validated mobile application identified autism on average 13 months earlier than the national average and as early as 18 months – when early intervention has the greatest potential for improved life-long outcomes.
DTx London Goes Online for 2020
With Digital Therapeutics hotter than they’ve ever been, the need to meet and learn together is greater than ever before. As an industry, we cannot afford to put things on hold.
DTx London 2020 has been completely re-engineered to deliver the best networking experience together with exciting new learning opportunities.
Replicate those all-important ‘water cooler’ moments through randomly assigned networking or join topic-associated discussions to find those with similar interests to you. Scroll through the entire attendee list to message your fellow attendees, schedule 1-2-1 video calls, or create your own private session rooms for group discussions. DTx London will enable you to meet more leaders from across the industry than ever before!
The agenda is purposely built to provide an engaging and interactive learning experience. integrated polls, topic-focused roundtables, Q&A with speakers, “Open-Mic” discussions, and more, you will be able to accelerate your knowledge of Digital Therapeutics as they continue their meteoric rise. The ability to actively or passively be involved in these learning opportunities is yours!
The Digital Platform lets you create your own personal agenda. You can attend live sessions, watch on-demand content, take part in open networking sessions, or take a break whenever suits you. Seamlessly hop between learning and networking at any time. Look through the program and slot sessions directly into your calendar, to help fit the conference around the day job. All of this from the comfort of your own home.
“I found this conference eye-opening and had many interesting conversations. I am blown away by the Digital Therapeutics community and its commitment to value-based care”
“DTx is the must attend event in our industry”
“The DTx Series is a fantastic set of meetings. The quality of the investors, entrepreneurs and companies never fails to impress me, and I always leave having learned a lot”
“The conference was tangible, specific and open. I have never been to a conference of this size with such richness of discussion”
“Thanks for catalyzing the industry forward in this emerging field. Looking forward to the next one”
“DTx is an inclusive event, where the participants truly believe that the rising tide will raise all boats”
Expert Speaker Faculty
Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.
Kim Baden-Kristensen is the CEO and Co-founder of Brain+, an award winning Danish health tech company specializing in digital therapeutics for neurorehabilitation of disorders and injuries to the Central Nervous System (CNS).
Kim is intensively engaged in digital health care policy debates and initiatives on the European level. He is a founding member of the Digital Therapeutics Partnership, a global non-for-profit with a mission to enhance patient outcomes and quality of care with clinically-validated digital therapeutics.
Kim is an expert within digital therapeutics, with particularly emphasis on neurogame-based rehabilitation and gamified behavioral therapy.
Kim holds an MSc. In Innovation Management from Copenhagen Business School, a Health Care Innovation Management degree from Harvard Business School, and a minor in Cognitive Neuroscience from Copenhagen University.
Heather is a master synergizer, with an enthusiastic curiosity for identifying innovative technologies and approaches to tackle major health care market needs.
Heather has spent the majority of her career focused on delivering game-changing innovation. Before Optum Ventures, she was senior director of new ventures & transactions at Johnson & Johnson Innovation, London. She has over 10 years of experience in the venture capital industry, gained while working for both early stage technology funds and corporate venture groups and has invested in a broad range of opportunities from medical devices to digital and consumer health care. Heather started her career at Unilever and holds a B.S. in Biochemistry and PhD in Clinical Biochemistry both from Queen’s University, Belfast.
Lana is the Managing Director of Hikma Ventures which she helped establish in 2015. Lana started her career at Hikma Pharmaceuticals PLC in 2012 as the Assistant to the CEO and Director of Corporate Strategy & Development where she worked on strategic projects across the company’s various functions including strategy, M&A, operations and finance. Prior to joining Hikma, Lana worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries. Currently, Lana heads the Innovation & Leadership Advisory Board (ILAB) at Hikma which consists of young Hikma employees whom share a dedication to advancing Hikma and ensuring it is at the frontier of innovation.
Lana holds an MBA from Harvard Business School (HBS) and a Bachelors of Commerce degree from McGill University.
Prayat leads enterprise sales to insurance, pharmaceutical and med device companies. Previously, he was a management and healthcare consultant at KPMG and PWC. He has an MBA from the Indian School of Business and a Bachelors in Science from Nanyang Technical University, Singapore. Hailing from a family of doctors, chronic disease management comes as a second skin.
Dom Raban is CEO and co-founder of Xploro, a Digital Therapeutics platform which uses augmented reality, artificial intelligence and games to help reduce the anxiety experienced by young patients going in to hospital. Dom established Xploro after his daughter had recovered from cancer treatment and he realised the importance of providing patients with information about their treatment – something that was lacking in his daughter’s experience.
Dom has been creating ‘stuff’ for over 40 years, from punk fanzines in the 1970s to content for emerging technology platforms now. He’s been in the digital space since the start, building his first website in 1995 and his first 3D virtual environment in 1996. He is also Chair of Corporation Pop, a digital innovation agency that specialises in a user-centred design approach to develop apps, games and software.
Christopher Scales is Director of Strategy & Insight for Star. A seasoned specialist in design strategy & corporate innovation, Christopher has 20 years of experience working with top-tier organisations defining and developing breakthrough products and services.
Lorenzo is co-founder and CEO of NuvoAir a digital therapeutics company focused on respiratory care.
Prior to founding NuvoAir, Lorenzo worked at Novartis as Innovation Director in the Digital Solutions team. Lorenzo holds an MBA from the Wharton School, University of Pennsylvania.
Previously Studio Director at Gameloft Madrid – a company developing and editing videogames –, Edouard is leading the Tilak Healthcare team. Before heading the Madrid Creation Studio, Edouard successively worked at Gameloft as Project Manager in Paris, then Lead Producer in New Orleans. He was also a writer for TechCrunch France, covering mobile apps, 2.0 web and entertainment topics. In 2011, he co founded Productism, a social commerce website.
Pritam Potnis is the Director of Strategy and Co-Lead for IQVIAs’ Digital Therapeutics Platform – AppScript. In this role, he is responsible for developing and executing global offering strategies across the AppScript platform both externally and within IQVIA networks.
Pritam joined IQVIA from DXC Technologies, a healthcare and life science technology services company where he worked extensively in payer, provider and life science segments. Part of the core team that developed DXC’s open data strategy and digital health platform, Pritam has served in successive product management and strategy roles, including the development and global launch of products and programs like Open Health Connect at New York Presbyterian Hospital, Digital Health – Egypt Ministry of Health, Apollo Hospitals India, Chronic Care Management among several others.
Pritam has a proven track record working with board-level executives and senior managers to provide business vision and strategic direction across the Healthcare and Life Sciences. Pritam has an M.S. in Computer Engineering from the Syracuse University and a B.S. in Engineering from the University of Mumbai.
Ray joins DIGITALEUROPE with over 20 years of government affairs and communications experience in Brussels and across the EMEA region. Previously, he worked at Microsoft being part of the team responsible for the strategies to improve relations with governments and position the company on socio-economic issues. Ray leads the digital transformation strategy to leverage DIGITALEUROPE’s expertise in key policy areas such as data protection, media, platform and consumer issues to create an important dialogue between industries being disrupted by technology and guidance to European regulators.
Ray leads several Policy and Working Groups helping our members advance important work in areas which includes artificial intelligence, skills development and the free flow of data. Areas that will be vital to unlock the full potential in Europe to deliver jobs, prepare children in education systems to be able to exploit important technologies and ensure Europe is a leader in creating world-class technology companies.
Ray holds citizenship with both Canada and France and is a graduate of McGill University in Political Science.
Ash is a Principal based in the London office of Optum Ventures, a digital health-focused investment group. Before Optum Ventures, Ash served as a lead life sciences investor and Head of Research for Mercia Asset Management, one of the most active investors in the UK. Prior to this, he served as Clinical Technology Director as part of the team that launched Babylon Health, a European health tech unicorn.
He started his career as an anaesthetics and intensive care doctor in the UK where he was involved in academic research work and clinical practice. He holds a M.A. and medical degree from the University of Oxford, and is a member of the CFA Institute, London
Jenny has spent over 25 years working on patient empowerment, co-existing with Rheumatoid Arthritis since 1994 has made that inevitable. In different settings she has driven the topic and projects to move the positions forward for true patient centricity.
Proving that advocacy doesn ́t always have to be driven by a patient organization.
Jenny is currently Chief Patient Officer at Elsa Science AB and serves as a constant reminder of the importance of including patients in all steps while developing a patient empowering solution. Bridging users/patients, HCPs, academia, payors and pharma is an important part in the everyday development of the tool Elsa.
Over a period of 9 years she drove the importance of patient inclusion in development as a Patient Relations Manager at Abbott/AbbVie. Developing co-created collaborations within Immunology in Sweden, Europe and Globally.
Jenny also holds 4 consecutive titles as Swedish Champion in Para Equestrian Dressage.
Abhishek has more than a decade of healthcare experience, having previously co-led an early stage fund as a venture capitalist, and held leadership positions in his healthcare family businesses. He holds a B.S. in Chemical and Biomolecular Engineering from Georgia Tech and an MBA from the Indian School of Business (ISB). He co-founded Wellthy Therapeutics in 2015 with the mission to reverse, prevent and control chronic conditions in India and Asia through clinically validated digital therapeutics.
Ed leads EVERSANA Management Consulting’s EMEA practice helping healthcare companies make better strategic decisions in the areas of commercialization, market entry, and partnering. He has served many companies in biopharma, diagnostics, medical devices, and has helped multiple DTx companies to develop their business models.
Prior to EVERSANA Management Consulting, Ed was a Partner at the boutique pharmaceutical consultancy Novasecta, where he supported senior leaders with commercial and corporate strategy challenges. He has spent 14 years working at pharmaceutical companies
Ed has an MA in biological sciences from Brasenose College, University of Oxford.
Dr Ciara Clancy is founder and CEO of Beats Medical, a digital therapeutics company specialising in neurological and CNS conditions.
Clancy holds a degree in Physiotherapy and a PhD in Neurosurgery outcomes. Her entrepreneurial work has been internationally recognised including selection for Forbes 30 under 30, Laureate for Europe in the Cartier Awards and a finalist in the EY Entrepreneur of the Year Awards.
Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.
Francesca Domenech Wuttke, Ph.D. is the Chief Digital Officer of Almirall where she is developing and executing an end-to-end companywide digital transformation. She is responsible for finding use cases across R&D, commercial, manufacturing, finance, legal and HR to apply digital solutions and services to bring efficiencies in terms of time and cost and to open up new business channels for Almirall.
Dr. Wuttke brings with her broad drug development and healthcare expertise in both the US and Europe, with over 20 years of clinical, commercial, strategic and transactional experience. She has worked with diverse organizations including start-ups, consulting, large and specialty pharma as well as academia.
Most recently, she led European investments as Managing Director for the MSD Global Health Innovation Fund, LLC. Previously Dr. Wuttke led Almirall´s Corporate Development Strategy team to transact on both med device and pharma M&A opportunities with a new and targeted focus for the company. Before that Dr. Wuttke worked at Novartis where she was responsible for two Cell and Gene therapy opportunities that were successfully brought into the organisation as well as managing the strategy and commercialisation for the existing portfolio of cell therapy assets.
Dr. Wuttke holds a Ph.D. in Pharmacology from Weill Cornell Graduate School of Medical Sciences and a BA from Cornell University College of Arts and Sciences.
Elena Mustatea is Co-founder and CEO of Bold Health, a startup developing digital therapeutics for functional and autoimmune conditions, leveraging behavioural medicine and machine learning to deliver personalised and highly effective treatments and self management support. Elena was named Forbes’ Europe 30 Under 30 Finance List in 2018 in her role as venture capital investor with leading European VC fund Atomico, and previously also worked in investment banking at J.P. Morgan and Goldman Sachs, management consulting at Oliver Wyman, and ran a media business.
Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.
Dr. Maroof Ahmed is a medical doctor who graduated from Imperial College London with dual degrees in Medicine and Business Management. He is the co-founder and COO of Digital Therapeutics.
Maroof spent 4 years conducting academic research in the fields of neurology, behavioural change, digital health and smoking cessation. He has published multiple peer-reviews papers on these topics and also acts as a reviewer for JMIR.
Whilst training to become a doctor, Maroof saw the impact smoking had on the lives of the patients around him and wanted to make a difference. So together with his co-founders, they put on hold their clinical careers to pursue Quit Genius full-time. This was a tough decision but they made this choice as it will allow them to make an impact on the lives of people worldwide at scale.
Carmen is an expert in digital transformation, having worked in a variety of high-pressure roles in technology as an entrepreneur & setting up international operations for Blue-Chip companies.
She currently leads the International efforts of Limbix, a Sequoia-backed startup building a pipeline of prescription digital therapeutics that combine the use of Virtual Reality (VR) & mobile apps to deliver cognitive-behavioural therapy to treat mental health conditions. The company has become the leader in the Digital Mental Health space thanks to its partnerships with top universities and hospitals.
Fluent in six languages and all about helping businesses contribute to a better world. Carmen is also passionate about bringing people together through her love of Spanish food.
Dennis is VP of business development & corporate finance at Kaia Health, a start-up developing individualised digital therapies for chronic diseases with a focus on backpain and respiratory conditions.
Prior to joining Kaia Health, Dennis was the COO of Oro de Cacao, where he led the scale-up process and financing rounds, and advised clients on Private Equity and Real Estate investments at 1875 FINANCE.
Donna became the Executive Director of EFNA in June 2012. Donna’s training is in Journalism, but she has worked with patient organisations in the neurological sector – in various roles – since leaving university. This included work with the European Migraine and Headache Alliance [EMHA] and the Migraine Association of Ireland [MAI], as well as being a representative to the Neurological Alliance of Ireland. Donna oversees the strategic direction of EFNA and leads in the creation and implementation of its annual workplan, projects and activities. Since joining EFNA, Donna has led the development of some of EFNA’s current keynote initiatives such as its MEP Interest Group on Brain, Mind and Pain and Training Initiatives for Neurology Advocates. She is also active in representing EFNA and the neurology patient community externally, including as a current Board Member of the European Brain Council and as a Member of the European Academy of Neurology’s European Affairs Sub-Committee.
Hakim is a Co-Founder and chief executive of Closed Loop Medicine. He joined CLM from the Northern Health Science Alliance Ltd, the pan-Northern health partnership which brought together for the first time 20 research-based NHS hospitals, the North’s Academic Health Science Networks and Universities to collaborate on improving health outcomes across the North.
As the founding CEO of the NHSA, Hakim was instrumental in raising the profile of the region in parliament, with investors and the media to help focus resources on improving healthcare services for the 15 million population living in the North and its eight great cities. Central to the NHSA’s mission was to raise awareness of the region’s high mortality rates and to seek national solutions to improve these morbidity levels by working with all local agencies to improve health – and therefore wealth and well-being -outcomes.
Hakim was also highly successful in working with companies in the North to attract substantial domestic and overseas investment into the region’s life science sector, one of the most vibrant in the country.
Having worked with specialist drug and digital companies all around the world, he has a deep understanding of innovation systems integration.
Hakim started his career at PA Consulting, where he co-managed the company’s translational medicine team. During his time at PA, he was seconded to the UK Government where he worked as the Chief Operations Officer and was a founding member of the UK Department of International Trade (DIT) Life Sciences Organisation (LSO).
He holds a PhD from the University of Cambridge and in 2017 he was awarded an OBE for services to Healthcare Technology and the Economy.
Dr Mala Mawkin MBBS, BSc (Hons), FICSM is an award winning medical doctor who trained at Imperial College London. Mala has previously worked with institutions such as the European Space Agency, Harvard University and several London Medical Technology companies. Mala was a Trustee for the century old Medical Women’s Federation UK for 3 years, listed on the Tech London 25 Under 25 and was one of two in her graduating cohort of 300 to be awarded a Fellowship of Imperial College School of Medicine. She is currently an appointed Council Member for the Royal Society of Medicine Digital Health Council.
Mala was featured on the Forbes 30 Under 30 list for Science & Healthcare, and also on Forbes 30 Under 30 Europe Youngest list. She was featured in 2018 Vogue Magazine as 10 Rising Female Stars for a feature publication with Nike and Naomi Campbell. Mala was also interviewed by Makers for a Barbie Be Inspired #closethedreamgap workshop for Women in Science. In 2019, Mala was selected as a “highly commended” finalist at the UK Women of the Future Awards.
Mala won the grand prize in a national competition run by the UK Space Agency for work discussing the future of space flight. From this, she was invited to NASA for 10 days. Mala was a runner up in the AXA Ambition Awards for Science and was awarded £10,000. Mala completed a 3 month medical research project at the European Space Agency (ESA), Germany. There she investigated glucose tolerance in European astronauts that flew in Shuttle missions. She then presented her work at Imperial and the UK Space Agency.
For her volunteer work Mala was awarded the Imperial College School of Medicine Alumni Award for Pastoral, Charitable and Community. She was also awarded Young Volunteer of the Year by her local council.
She has worked for leading medical technology startups in London as well as working with brands such as Unilever, Microsoft Health and Uber. Mala is a keen writer and has written as an official blogger for Imperial College London for 6 years, was The Times student ambassador and has written feature articles for The Guardian.
Mala has a BSc in Global Health and furthered her interest by undertaking an e-health research project in Malawi, and later presented the work internationally. She has also worked within the Digital Health team at Harvard University & Boston Children’s Hospital. Mala has co-authored research papers in anaesthesia in extreme environments providing considerations for future space exploration missions as well as research in medical technology for surgery training.
Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.
Anish Shindore is the Head of Digital Therapeutics at Sanofi, a company focused on empowering lives through human health.
Anish’s focus is in identifying opportunities within different towards a new standard of care. therapeutic areas and driving and transforming Sanofi for creating new and accelerating existing digital therapeutics (DTx) opportunities.
Anish joined Sanofi from a career within Digital & other commercial roles at a country and global level (Novartis).
Since his immersion in Pharma, Anish has been closely involved with numerous technology and software startup companies focused on health. His passion is to create human centric digital solutions based on data, blending insights and approaches across industries to solve complex health problems at scale.
Over the years, Anish has been actively mentoring people from various industries, helping them to first clarify and then realize their true potential. Faculty, at Geneva Business School; Advisor, to multiple start-ups; Seed stage Investor and firm believer in Human + Tech = Healthcare of now & future.
Anish earned his MBA from ESADE and holds two bachelor’s degrees in business from Georgia State University and University of Pune.
Dr. Jorge E Palacios is a clinical researcher for SilverCloud Health, as well as a member of the e-mental health research group at Trinity College Dublin. He is involved in several research projects, focusing on delivering internet-based psychological therapy to diverse clinical and non-clinical populations. He completed his PhD in Psychological Medicine, at the Institute of Psychiatry, Psychology, and Neuroscience (IoPPN), King’s College London, where he worked on trajectories of depression and anxiety symptomatology in Coronary Heart Disease. He recently was awarded the Young Investigator of the Year prize from Elsevier and the European Association of Psychosomatic Medicine, presented in Barcelona in 2017. Dr. Palacios completed his medical degree in Mexico before moving to London to undertake a master’s degree in Psychiatric research, which he passed with distinction in 2012.
Damien leads global strategic alliances at Voluntis. He is also charged with extending Voluntis’ RWE capabilities, notably in the fields of outcomes measurement and data valuation. Damien trained in the UK as a pharmacist and also studied computing. He has over a decade of hands-on experience in digital therapeutics supporting pharmaceuticals and medical devices. He started his career in frontline clinical roles in Portsmouth Hospitals NHS Trust and then in retail pharmacies. At AXA he helped build an operational framework to handle outsourced medical and safety information services for pharmaceutical partners. In 2005 he led the preparation for the first ever UK MHRA inspection of this type of provider. He joined Voluntis in Paris in 2008 to take the helm of its quality division, obtaining QMS certification for ISO:13485 in 2010 and a first-in-world regulatory clearance of an insulin titration application in 2013, CE mark of Diabeo.
As an experienced leader in digital healthcare, Stefan Scheepers is Business Director, European Healthcare and Lifesciences, Mobiquity.
Before this, Stefan rose through the ranks at KPN occupying multiple senior leadership positions as a pioneer of digital healthcare innovation.
Stefan champions a human-centric approach to enable ownership of one’s own health.
Digital Conference Platform
The Digital conference platform is purpose-built to enable us to provide you with a more personal experience.
For starters, no more wondering who is in the room! View and message the entire attendee list. If that’s not enough, there are a multitude of structured and unstructured networking opportunities to give you the chance to reconnect with old friends and meet your future collaborators.
Then there’s the learning. Through an engaging and interactive agenda, you will be able to actively or passively participate as much as you’d like. From polls and Q&A through to open discussions and dedicated roundtables, it has never been easier to accelerate your knowledge of Digital Therapeutics.
Imagine the possibilities of this digital event! Networking with your peers, learning from the experts, collaborating, and shaping the future of Digital Therapeutics – all on a world-class, purpose-built platform.
Partner With Us
DTx London being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together the best DTx audience of the year.
Making your session engaging and knowledgeable will attract the largest audience. We will guide you on how best to maximize the benefits of using our platform.
No need to sit behind a desk! Our networking tools enable attendees to arrange 121 video conversations as well as take part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.
Get in touch to learn more about the options available at DTx London.
Register for the Event
For pricing and booking options please click the button to go to the registration page.